CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Xagena Salute
Ematobase.it

Search results for "Sacubitril"

The PARADIGM-HF ( Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure ) trial has demonstrated that a new angiotensin receptor antagonist - ...


The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared with Enalapril in patients with chroni ...


A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF ) treated with Entresto ( Sacubitril / Valsartan ) tablets were readm ...


The combination drug Valsartan / Sacubitril known as LCZ696 ( Entresto ) significantly reduced aortic systolic blood pressure and pulse pressure compared to the standard angiotensin receptor blocker ( ...


European Society of Cardiology ( ESC ) Guidelines for the diagnosis and treatment of acute and chronic heart failure are published in European Heart Journal and the European Journal of Heart Failure, ...


A study assessed whether the benefit of Sacubitril / Valsartan ( Entresto ) therapy varied with clinical stability. Despite the benefit of Sacubitril / Valsartan therapy shown in the PARADIGM-HF ( ...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac death and hospitalization due to heart failure. Now, researchers from Kuma ...


The quality of evidence regarding patient-centered outcomes in adults with heart failure after Sacubitril combined with Valsartan ( Entresto ) has not been systematically appraised. An analysis ha ...


Sacubitril / Valsartan ( Entresto ) has been shown to improve mortality and reduce hospitalizations in patients with heart failure with reduced ejection fraction ( HFrEF ). The effect of combination ...


Elevated serum uric acid concentration ( SUA ) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. Researchers have examined the as ...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany ) has shown that Entresto ( Sacubitril / Valsartan ) can be initiated early and safe ...


Because neprilysin is involved in the degradation of amyloid-beta, there is concern that the angiotensin-neprilysin inhibitor Sacubitril - Valsartan ( Entresto ) could increase the risk for dementia. ...


Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction ( HFrEF ), as shown in PARADIGM-HF which compared ...


Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of Sacubitril - Valsartan ( Entresto ) therapy is safe and eff ...


The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto ) versus the active comparator Valsartan in HFpEF ( heart failure wit ...